S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund
S&P 500   4,567.18
DOW   36,124.56
QQQ   387.29
Investing in quantum computing: A guide 
Energy Storage Trend Ignites Frenzy Over Vanadium Supply (Ad)
What is dividend harvesting?
Marvell Technology at a critical pivot: 30% upside is possible
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
What analysts wanted out of Chewy stock is finally here
Even Scrooge can’t pass up these 3 bargain stocks
[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity (Ad)
The truth about DocuSign's relevancy in today's world: Surprise
SoFi expands ETF business with options-driven income fund

IDEXX Laboratories Stock Price, News & Analysis (NASDAQ:IDXX)

$518.95
+2.34 (+0.45%)
(As of 12/5/2023 ET)
Compare
Today's Range
$507.93
$519.43
50-Day Range
$391.37
$518.95
52-Week Range
$372.50
$564.73
Volume
614,438 shs
Average Volume
467,229 shs
Market Capitalization
$43.10 billion
P/E Ratio
52.95
Dividend Yield
N/A
Price Target
$548.14

IDEXX Laboratories MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.71 Rating Score
Upside/​Downside
5.6% Upside
$548.14 Price Target
Short Interest
Bearish
3.37% of Float Sold Short
Dividend Strength
N/A
Sustainability
-2.09
Upright™ Environmental Score
News Sentiment
0.91mentions of IDEXX Laboratories in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
11.68%
From $9.85 to $11.00 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.27 out of 5 stars

Medical Sector

302nd out of 948 stocks

Diagnostic Substances Industry

2nd out of 12 stocks


IDXX stock logo

About IDEXX Laboratories Stock (NASDAQ:IDXX)

IDEXX Laboratories, Inc. develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. It also provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments, and services for biomedical research community. In addition, the company offers diagnostic and health-monitoring products for livestock, poultry, and dairy products that test water for various microbiological contaminants; point-of-care electrolytes and blood gas analyzers; OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing; in-clinic chemistry, blood and urine chemistry, hematology, immunoassay, urinalysis, and coagulation analyzers; and SNAP rapid assays test kits. Further, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; and veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

IDXX Stock Price History

IDXX Stock News Headlines

U.S. Military Defense Fails Without Vanadium?
The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.
IDEXX Laboratories (NASDAQ:IDXX) Upgraded at StockNews.com
ALC or IDXX: Which Is the Better Value Stock Right Now?
IDEXX Laboratories (IDXX) Fell on Investors’ Concerns
U.S. Military Defense Fails Without Vanadium?
The metal vanadium is needed for numerous military applications, including jet engines, airframes, and ballistic missiles. And although the U.S. Govt. considers vanadium critical to national security, less than 5% of the metal is mined in America. This means we're at the mercy of China and Russia for our supply.
IDEXX Laboratories Inc IDXX
IDXX Jan 2024 380.000 put
5 Analysts Have This to Say About IDEXX Laboratories
Q3 2023 IDEXX Laboratories Inc Earnings Call
IDEXX Labs Lifts FY23 Earnings View, Cuts Revenue Forecast - Update
IDEXX Laboratories Inc Q3 Income Climbs, Beats estimates
IDEXX Laboratories's Earnings: A Preview
Is IDEXX Laboratories (NASDAQ:IDXX) A Risky Investment?
See More Headlines
Receive IDXX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEXX Laboratories and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/01/2023
Today
12/05/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/05/2024

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
Health Care Equipment
Sector
Medical
Current Symbol
NASDAQ:IDXX
CUSIP
45168D10
Employees
10,780
Year Founded
1983

Price Target and Rating

Average Stock Price Target
$548.14
High Stock Price Target
$610.00
Low Stock Price Target
$460.00
Potential Upside/Downside
+5.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.71
Research Coverage
7 Analysts

Profitability

Net Income
$679.09 million
Pretax Margin
28.84%

Debt

Sales & Book Value

Annual Sales
$3.37 billion
Cash Flow
$10.27 per share
Book Value
$7.35 per share

Miscellaneous

Free Float
81,300,000
Market Cap
$43.10 billion
Optionable
Optionable
Beta
1.23

Social Links

5G Stocks: The Path Forward is Profitable Cover

Click the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Should I Buy IDEXX Laboratories Stock? IDXX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of IDEXX Laboratories was last updated on Sunday, December 3, 2023 at 5:09 PM.

Pros

Here are some ways that investors could benefit from investing in IDEXX Laboratories, Inc.:

  • Strong presence in multiple markets: IDEXX Laboratories operates in the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide, providing a diversified revenue stream.
  • Companion Animal Group segment: The company's Companion Animal Group segment offers point-of-care veterinary diagnostic products, veterinary reference laboratory diagnostic services, and practice management systems for veterinarians, which are in high demand and contribute to the company's growth.
  • Innovation in diagnostic products: IDEXX Laboratories develops and manufactures a wide range of diagnostic products, including rapid assay test kits, analyzers, and testing instruments. The company's continuous innovation in this area keeps it competitive in the market.
  • Expansion into human COVID-19 testing: IDEXX Laboratories has developed the OPTI SARS-CoV-2 RT-PCR test kit for human COVID-19 testing. This expansion into the human testing market presents a new growth opportunity for the company.
  • Strong distribution network: The company markets its products through various channels, including marketing, customer service, sales, and technical service groups, as well as independent distributors and resellers. This extensive distribution network helps IDEXX Laboratories reach a wide customer base.

Cons

Investors should be bearish about investing in IDEXX Laboratories, Inc. for these reasons:

  • Competition in the market: IDEXX Laboratories operates in a highly competitive market, facing competition from other companies in the diagnostics and research industry. This competition could potentially impact the company's market share and profitability.
  • Regulatory challenges: As a healthcare equipment company, IDEXX Laboratories is subject to various regulations and compliance requirements. Changes in regulations or failure to comply with existing regulations could have a negative impact on the company's operations and financial performance.
  • Market volatility: The stock market can be volatile, and fluctuations in the market can affect the stock price of IDEXX Laboratories. Investors should be aware of the potential risks associated with investing in a volatile market.
  • Dependency on veterinary industry: IDEXX Laboratories heavily relies on the veterinary industry for its revenue. Any downturn or disruption in the veterinary industry could have a significant impact on the company's financial performance.
  • Potential impact of COVID-19: The ongoing COVID-19 pandemic has created uncertainties in the global economy and could potentially impact IDEXX Laboratories' business operations. Investors should consider the potential risks and challenges posed by the pandemic.














IDXX Stock Analysis - Frequently Asked Questions

Should I buy or sell IDEXX Laboratories stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for IDEXX Laboratories in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" IDXX shares.
View IDXX analyst ratings
or view top-rated stocks.

What is IDEXX Laboratories' stock price target for 2024?

7 equities research analysts have issued 1 year price objectives for IDEXX Laboratories' stock. Their IDXX share price targets range from $460.00 to $610.00. On average, they anticipate the company's share price to reach $548.14 in the next year. This suggests a possible upside of 5.6% from the stock's current price.
View analysts price targets for IDXX
or view top-rated stocks among Wall Street analysts.

How have IDXX shares performed in 2023?

IDEXX Laboratories' stock was trading at $407.96 at the beginning of the year. Since then, IDXX shares have increased by 27.2% and is now trading at $518.95.
View the best growth stocks for 2023 here
.

When is IDEXX Laboratories' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, February 5th 2024.
View our IDXX earnings forecast
.

How were IDEXX Laboratories' earnings last quarter?

IDEXX Laboratories, Inc. (NASDAQ:IDXX) announced its quarterly earnings data on Wednesday, November, 1st. The company reported $2.53 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.37 by $0.16. The firm had revenue of $915.53 million for the quarter, compared to analysts' expectations of $926.88 million. IDEXX Laboratories had a trailing twelve-month return on equity of 85.68% and a net margin of 22.93%. The company's revenue for the quarter was up 8.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.15 EPS.
Read the conference call transcript
.

What is Jay Mazelsky's approval rating as IDEXX Laboratories' CEO?

40 employees have rated IDEXX Laboratories Chief Executive Officer Jay Mazelsky on Glassdoor.com. Jay Mazelsky has an approval rating of 69% among the company's employees.

What other stocks do shareholders of IDEXX Laboratories own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEXX Laboratories investors own include NVIDIA (NVDA), Netflix (NFLX), PayPal (PYPL), Mastercard (MA), Adobe (ADBE), Tesla (TSLA), Alibaba Group (BABA), Block (SQ), Walt Disney (DIS) and Shopify (SHOP).

Who are IDEXX Laboratories' major shareholders?

IDEXX Laboratories' stock is owned by a number of institutional and retail investors. Top institutional investors include Bamco Inc. NY (2.81%), Invesco Ltd. (1.47%), Blair William & Co. IL (1.44%), Brown Advisory Inc. (1.40%), Morgan Stanley (1.28%) and Northern Trust Corp (1.11%). Insiders that own company stock include Brian P Mckeon, Brian P Mckeon, Daniel M Junius, Giovani Twigge, James F Polewaczyk, James F Polewaczyk, Jonathan Jay Mazelsky, Jonathan W Ayers, Kathy V Turner, Kathy V Turner, M Anne Szostak, Michael Lane, Nimrata Hunt, Rebecca M Henderson and Sophie V Vandebroek.
View institutional ownership trends
.

How do I buy shares of IDEXX Laboratories?

Shares of IDXX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:IDXX) was last updated on 12/6/2023 by MarketBeat.com Staff

My Account -